Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease.
Animals
Anticonvulsants
/ pharmacology
Behavior, Animal
/ drug effects
Cannabidiol
/ pharmacology
Ciliary Neurotrophic Factor
/ genetics
Disease Models, Animal
Dopaminergic Neurons
/ drug effects
Male
Neuroprotective Agents
/ pharmacology
Parkinson Disease
/ drug therapy
Rats
Rats, Sprague-Dawley
TRPV Cation Channels
/ genetics
6-hydroxydopamine
cannabidiol
ciliary neurotrophic factor
neuroinflammation
phytocannabinoids
transient receptor potential vanilloid 1
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
04
07
2021
revised:
14
08
2021
accepted:
16
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main phytocannabinoids identified in Cannabis Sativa, which exhibits a large spectrum of therapeutic properties, including anti-inflammatory and antioxidant effects, suggesting its potential as disease-modifying agent for PD. The aim of this study was to evaluate the effects of chronic treatment with CBD (10 mg/kg, i.p.) on PD-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine model. Moreover, we investigated the potential mechanisms by which CBD exerted its effects in this model. CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibits a preferential action on astrocytes and activates the astrocytic transient receptor potential vanilloid 1 (TRPV1), thus, enhancing the endogenous neuroprotective response of ciliary neurotrophic factor (CNTF). These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent.
Identifiants
pubmed: 34445626
pii: ijms22168920
doi: 10.3390/ijms22168920
pmc: PMC8396349
pii:
doi:
Substances chimiques
Anticonvulsants
0
Ciliary Neurotrophic Factor
0
Neuroprotective Agents
0
TRPV Cation Channels
0
Trpv1 protein, rat
0
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Pharmacol. 2021 Apr 28;12:641210
pubmed: 33995048
Br J Pharmacol. 2008 Jan;153(2):199-215
pubmed: 17828291
Transl Psychiatry. 2018 Sep 3;8(1):176
pubmed: 30177808
PLoS One. 2014 Dec 17;9(12):e113161
pubmed: 25517414
Int J Mol Sci. 2016 Dec 23;18(1):
pubmed: 28025562
Front Immunol. 2018 Aug 03;9:1782
pubmed: 30123217
Mov Disord. 2021 Jan;36(1):16-24
pubmed: 32357266
Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Mar;5(1):33-9
pubmed: 15204022
Int J Mol Sci. 2018 Nov 10;19(11):
pubmed: 30423807
J Mol Med (Berl). 2006 Mar;84(3):253-8
pubmed: 16389547
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:94-105
pubmed: 27889412
J Neurosci. 2012 Jul 4;32(27):9277-87
pubmed: 22764235
J Neurosci. 2010 Jun 2;30(22):7516-27
pubmed: 20519526
Mol Neurobiol. 2014 Feb;49(1):28-38
pubmed: 23783559
J Nat Prod. 2020 Jun 26;83(6):2025-2029
pubmed: 32374168
J Psychopharmacol. 2009 Nov;23(8):979-83
pubmed: 18801821
J Vis Exp. 2018 Jun 5;(136):
pubmed: 29939190
J Neuroinflammation. 2015 Mar 15;12:52
pubmed: 25880134
Glia. 2021 Sep;69(9):2133-2145
pubmed: 33956370
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
Front Pharmacol. 2017 Feb 03;8:20
pubmed: 28217094
Neurobiol Dis. 2013 Nov;59:141-50
pubmed: 23851307
Schizophr Res. 2015 May;164(1-3):155-63
pubmed: 25680767
Brain. 2015 Dec;138(Pt 12):3610-22
pubmed: 26490328
Neurotox Res. 2014 Nov;26(4):307-16
pubmed: 24532152
Neurochem Res. 2017 Dec;42(12):3431-3438
pubmed: 28861768
FEBS J. 2012 Apr;279(7):1156-66
pubmed: 22251459
Braz J Psychiatry. 2008 Sep;30(3):271-80
pubmed: 18833429
Nature. 1989 Dec 21-28;342(6252):920-3
pubmed: 2594085
Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107
pubmed: 15837565
Neuroscience. 1997 Mar;77(1):233-46
pubmed: 9044389
Front Aging Neurosci. 2017 Jun 08;9:176
pubmed: 28642697
Pharm Res. 2019 Dec 23;37(1):12
pubmed: 31873819
Trends Mol Med. 2002 Feb;8(2):58-61
pubmed: 11815270
Fitoterapia. 2017 Jan;116:77-84
pubmed: 27890794
Neuroscience. 2019 Sep 1;415:89-96
pubmed: 31325563
PLoS One. 2015 Apr 17;10(4):e0126450
pubmed: 25886143
J Neurochem. 2016 Oct;139 Suppl 2:136-153
pubmed: 26990767
Fitoterapia. 2016 Jul;112:104-15
pubmed: 27215129
J Neuroimmunol. 1993 Nov-Dec;48(2):177-87
pubmed: 8227315
Parkinsons Dis. 2011 Feb 15;2011:247467
pubmed: 21403820
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109745
pubmed: 31442553
Neurobiol Dis. 2010 Feb;37(2):434-40
pubmed: 19900555
Pharmacol Res. 2016 Oct;112:119-127
pubmed: 26845349
J Parkinsons Dis. 2018;8(s1):S3-S8
pubmed: 30584159
Aging (Albany NY). 2021 Apr 13;13(7):10796-10813
pubmed: 33848261
Sci Rep. 2018 Oct 25;8(1):15764
pubmed: 30361629
Nutrition. 2020 Jan;69:110494
pubmed: 31586482
Neuropharmacology. 2008 Dec;55(8):1280-6
pubmed: 18634812
J Neurosci Methods. 2006 Dec 15;158(2):219-23
pubmed: 16837051
Phytother Res. 2014 Jul;28(7):1007-13
pubmed: 24288245
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):326-336
pubmed: 33381646
Eur J Pharmacol. 2009 Jun 10;612(1-3):61-8
pubmed: 19285060
Exp Neurobiol. 2019 Apr;28(2):289-299
pubmed: 31138996
Neuropharmacology. 1996;35(11):1503-19
pubmed: 9025098
J Neurochem. 2004 Apr;89(1):134-41
pubmed: 15030397
J Psychopharmacol. 2014 Nov;28(11):1088-98
pubmed: 25237116
Br J Pharmacol. 2001 Oct;134(4):845-52
pubmed: 11606325
Brain Res. 2007 Feb 23;1134(1):162-70
pubmed: 17196181